title: Algorithmic guided screening of drug combinations of arbitrary size for activity against cancer cells.
abstract: The standard treatment for most advanced cancers is multidrug therapy. Unfortunately, combinations in the clinic often do not perform as predicted. Therefore, to complement identifying rational drug combinations based on biological assumptions, we hypothesized that a functional screen of drug combinations, without limits on combination sizes, will aid the identification of effective drug cocktails. Given the myriad possible cocktails and inspired by examples of search algorithms in diverse fields outside of medicine, we developed a novel, efficient search strategy called Medicinal Algorithmic Combinatorial Screen (MACS). Such algorithms work by enriching for the fitness of cocktails, as defined by specific attributes through successive generations. Because assessment of synergy was not feasible, we developed a novel alternative fitness function based on the level of inhibition and the number of drugs. Using a WST-1 assay on the A549 cell line, through MACS, we screened 72 combinations of arbitrary size formed from a 19-drug pool across four generations. Fenretinide, suberoylanilide hydroxamic acid, and bortezomib (FSB) was the fittest. FSB performed up to 4.18 SD above the mean of a random set of cocktails or "too well" to have been found by chance, supporting the utility of the MACS strategy. Validation studies showed FSB was inhibitory in all 7 other NSCLC cell lines tested. It was also synergistic in A549, the one cell line in which this was evaluated. These results suggest that when guided by MACS, screening larger drug combinations may be feasible as a first step in combination drug discovery in a relatively small number of experiments.
authors.affiliation: Department of Thoracic/Head and Neck Medical Oncology, Unit 432, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA. rzinner@mdanderson.org
authors.forename: Ralph G
authors.initials: RG
authors.lastname: Zinner
authors.forename: Brittany L
authors.initials: BL
authors.lastname: Barrett
authors.forename: Elmira
authors.initials: E
authors.lastname: Popova
authors.forename: Paul
authors.initials: P
authors.lastname: Damien
authors.forename: Andrei Y
authors.initials: AY
authors.lastname: Volgin
authors.forename: Juri G
authors.initials: JG
authors.lastname: Gelovani
authors.forename: Reuben
authors.initials: R
authors.lastname: Lotan
authors.forename: Hai T
authors.initials: HT
authors.lastname: Tran
authors.forename: Claudio
authors.initials: C
authors.lastname: Pisano
authors.forename: Gordon B
authors.initials: GB
authors.lastname: Mills
authors.forename: Li
authors.initials: L
authors.lastname: Mao
authors.forename: Waun K
authors.initials: WK
authors.lastname: Hong
authors.forename: Scott M
authors.initials: SM
authors.lastname: Lippman
authors.forename: John H
authors.initials: JH
authors.lastname: Miller
mesh_terms: D000465:Algorithms; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000737:chemistry* / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000473:pathology; D049109:Cell Proliferation / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D004354:Drug Screening Assays, Antitumor / Q000379:methods*; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008970:Molecular Weight; D011355:Prodrugs / Q000737:chemistry / Q000627:therapeutic use; D014407:Tumor Cells, Cultured
chemical_list: D011355:Prodrugs